Background: Glycated hemoglobin A1c (HbA1c) among diabetic hemodialysis patients continues to be the standard of care, although its limitations are well recognized. This study evaluated glycated albumin (GA) and glycated serum protein (GSP) as alternatives to HbA1c in detecting glycemic control among diabetic hemodialysis patients using continuous-glucose-monitoring (CGM)-derived glucose as reference standard. Methods: A CGM system (iPRO) was applied for 7 days in 37 diabetic hemodialysis patients to determine glycemic control. The accuracy of GA and GSP versus HbA1c in detecting a 7-day average glucose ≥184 mg/dL was evaluated via receiver-operating-characteristic (ROC) analysis. Results: CGM-derived glucose exhibited strong correlation (r = 0.970, p < 0.001) and acceptable agreement with corresponding capillary glucose measurements obtained by the patients themselves in 1,169 time-points over the 7-day-long CGM. The area under ROC curve (AUC) for GA, GSP, and HbA1c to detect poor glycemic control was 0.976 (0.862–1.000), 0.682 (0.502–0.862), and 0.776 (0.629–0.923) respectively. GA levels >20.3% had 90.9% sensitivity and 96.1% specificity in detecting a 7-day average glucose ≥184 mg/dL. The AUC for GA was significantly higher than the AUC for GSP (difference between areas: 0.294, p < 0.001) and the AUC for HbA1c (difference between areas: 0.199, p < 0.01). Conclusion: Among diabetic hemodialysis patients, GA is a stronger indicator of poor glycemic control assessed with 7-day-long CGM when compared to GSP and HbA1c.

Keywords:
Glycated albumin, Glycated serum protein, Glycated hemoglobin A1c, Continuous glucose monitoring, End-stage renal disease, Hemodialysis
1.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.
2.
Tonelli M, Wiebe N, Culleton B, et al: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034–2047.
3.
Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM: Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503–1509.
4.
Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K: Updates on the management of diabetes in dialysis patients. Semin Dial 2014; 27: 135–145.
5.
Parrinello CM, Selvin E: Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr Diab Rep 2014; 14: 548.
6.
Speeckaert M, Van Biesen W, Delanghe J, et al: Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant 2014; 29: 2167–2177.
7.
American Diabetes Association: Standard of medical care in diabetes – 2017. Diabetes Care 2017; 40(supp 1):S1–S135.
8.
Perkovic V, Agarwal R, Fioretto P, et al: Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int 2016; 90: 1175–1183.
9.
Anguizola J, Matsuda R, Barnaby OS, et al: Review: glycation of human serum albumin. Clin Chim Acta 2013; 425: 64–76.
10.
Inaba M, Okuno S, Kumeda Y, et al: Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896–903.
11.
Peacock TP, Shihabi ZK, Bleyer AJ, et al: Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73: 1062–1068.
12.
Chen CW, Drechsler C, Suntharalingam P, Karumanchi SA, Wanner C, Berg AH: High glycated albumin and mortality in persons with diabetes mellitus on hemodialysis. Clin Chem 2017; 63: 477–485.
13.
Freedman BI, Andries L, Shihabi ZK, et al: Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011; 6: 1635–1643.
14.
Yamada S, Inaba M, Okada S, et al: Association of glycated albumin, but not glycated hemoglobin, with calcaneus quantitative ultrasound in male hemodialysis patients with type 2 diabetes mellitus. Metabolism 2010; 59: 390–394.
15.
Gai M, Merlo I, Dellepiane S, et al: Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis. Blood Purif 2014; 38: 68–73.
16.
Jung HS, Kim HI, Kim MJ, et al: Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system. Diabetes Technol Ther 2010; 12: 801–807.
17.
Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, et al: Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 2009; 32: 1137–1142.
18.
Riveline JP, Teynie J, Belmouaz S, et al: Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 2009; 24: 2866–2871.
19.
Reach G, Choleau C: Continuous glucose monitoring: physiological and technological challenges. Curr Diabetes Rev 2008; 4: 175–180.
20.
Montagnana M, Paleari R, Danese E, et al: Evaluation of biological variation of glycated albumin (GA) and fructosamine in healthy subjects. Clin Chim Acta 2013; 423: 1–4.
21.
Hoshino J, Molnar MZ, Yamagata K, et al: Developing an HbA(1c)-based equation to estimate blood glucose in maintenance hemodialysis patients. Diabetes Care 2013; 36: 922–927.
22.
Agarwal R, Light RP: Relationship between glycosylated hemoglobin and blood glucose during progression of chronic kidney disease. Am J Nephrol 2011; 34: 32–41.
23.
Nagayama H, Inaba M, Okabe R, et al: -Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test. Biomed Pharmacother 2009; 63: 236–240.
24.
Kumeda Y, Inaba M, Shoji S, et al: Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol (Oxf) 2008; 69: 556–561.
25.
Murea M, Moran T, Russell GB, et al: Glycated albumin, not hemoglobin A1c, predicts cardiovascular hospitalization and length of stay in diabetic patients on dialysis. Am J Nephrol 2012; 36: 488–496.
26.
Selvin E, Francis LM, Ballantyne CM, et al: Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 2011; 34: 960–967.
27.
Morgan L, Marenah CB, Jeffcoate WJ, Morgan AG: Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med 1996; 13: 514–519.
28.
Joy MS, Cefalu WT, Hogan SL, Nachman PH: Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297–307.
29.
Képénékian L, Smagala A, Meyer L, et al: Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study. Clin Nephrol 2014; 82: 240–246.
30.
Joubert M, Fourmy C, Henri P, Ficheux M, Lobbedez T, Reznik Y: Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract 2015; 107: 348–354.
31.
Sacks DB, Arnold M, Bakris GL, et al: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011; 34:e61–e99.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.